Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Apellis Pharmaceuticals Inc

CUSIP: 03753U956 | 14 institutional holders

Quarters

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Compare Detailed Historical Funds Options 13D/13G Peers Targeting Trading Summary Profile